Showing results (81-90 of 132) with videos related to
Sort By:
Pageof 14
Antimicrobial Agents and Chemotherapy|February 4, 2009
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjectsGraeme Moyle, Marta Boffito, Carl Fletcher, et al.Journal of the International AIDS Society|November 15, 2014
Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitorMartin Fisher, Cheryl McDonald, Graeme Moyle, et al.Wellcome Open Research|November 19, 2021
Rapid design and implementation of an adaptive pooling workflow for SARS-CoV-2 testing in an NHS diagnostic laboratory: a proof-of-concept studyMichael Crone, Paul Randell, Zoey Herm, et al.Lancet (London, England)|August 30, 2008
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyJean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarria, et al.The Journal of Infection|August 8, 2021
Real-world evaluation of COVID-19 lateral flow device (LFD) mass-testing in healthcare workers at a London hospital; a prospective cohort analysisGeorgia Lamb, Joseph Heskin, Paul Randell, et al.AIDS (London, England)|March 7, 2025
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruptionGraeme Moyle, Joshua Gruber, Megan Dunbar, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2024
Antiretrovirals and Weight Change: Weighing the EvidenceDavid Alain Wohl, John R Koethe, Paul E Sax, et al.Medical Oncology (Northwood, London, England)|March 15, 2018
Blood Epstein-Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphomaIkram Ul-Haq, Alessia Dalla Pria, Elisa Suardi, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2010
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionJulian Falutz, Diane Potvin, Jean-Claude Mamputu, et al.Antimicrobial Agents and Chemotherapy|May 26, 2010
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjectsGraeme Moyle, Marta Boffito, Albrecht Stoehr, et al.Pageof 14